Clinical Trial Update: Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab in combination with chemotherapy after surgical resection in malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Chemotherapy (chemotherapy)
• OPDIVO (nivolumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Pleural Mesothelioma Malignant | Phase 2 | Status: COMPLETED